BeOne Shows Promising Breast Cancer Data at ASCO 2025
June 2, 2025
Preliminary results highlight anti-tumor activity and favorable safety profiles of both B7-H4-targeting ADC and CDK2 inhibitor BeOne Medicines Ltd. , a global oncology company, announced new